StreetInsider.com News Articles

Neuphoria confirms acquisition talks with Scancell Holdings

Fri, 26 Jun 2026 16:15:40 -0400

Neuphoria Therapeutics Inc. (NASDAQ: NEUP) confirmed it is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition of Neuphoria by Scancell, according to a statement from the company's board.

The board's statement came in response to an announcement made by Scancell, which was issued following speculation in the UK press and in compliance with UK regulations. Under the terms being discussed, Scancell would become a Nasdaq-listed company following the closing of any such transaction.

Neuphoria cautioned that there is no certainty that any agreement will be reached, nor any assurance regarding the terms of a potential transaction or whether a

Neuphoria confirms acquisition talks with Scancell Holdings

Fri, 26 Jun 2026 16:15:40 -0400

Neuphoria cautioned that there is no certainty that any agreement will be reached, nor any assurance regarding the terms of a potential transaction or whether a

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Fri, 26 Jun 2026 16:15:00 -0400

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc (“Scancell”).

The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made following

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Fri, 26 Jun 2026 16:15:00 -0400

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made following

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Fri, 26 Jun 2026 16:15:00 -0400

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made following

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Fri, 26 Jun 2026 16:15:00 -0400

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made following

Form 8-K Neuphoria Therapeutics For: May 21

Tue, 26 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260526/26550191.html

Form 8-K Neuphoria Therapeutics For: May 21

Tue, 26 May 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260526/26550191.html

H.C. Wainwright Downgrades Neuphoria Therapeutics Inc. (NEUP) to Neutral

Fri, 15 May 2026 12:56:17 -0400

H.C. Wainwright analyst Joseph Pantginis downgraded Neuphoria Therapeutics Inc. (NASDAQ: NEUP) from Buy to Neutral.

For an analyst ratings summary and ratings history on Neuphoria Therapeutics Inc. click here. For more ratings news on Neuphoria Therapeutics Inc. click here.

Shares of Neuphoria Therapeutics Inc. closed at $5.09 yesterday.

Form 10-Q Neuphoria Therapeutics For: Mar 31

Fri, 15 May 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26500163.html

Form 10-Q Neuphoria Therapeutics For: Mar 31

Fri, 15 May 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260515/26500163.html

ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

Mon, 08 Dec 2025 08:01:43 -0400

Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company’s director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital Management (“Lynx1”) is conducting a proxy contest and is seeking the election at the 2025 Annual Meeting of two director candidates in opposition to the highly

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees